Pfizer

Pfizer still seeking CROs for U.K. site

Thursday, June 2, 2011 11:21 AM

Pfizer continues to search for CROs to occupy a U.K. site, but the local council is disappointed by the lack of government action.

More... »

Pfizer strategically partners with Icon, Parexel

Thursday, May 26, 2011 11:53 AM

Pfizer today doled out two large strategic partnership agreements, which have become the brass ring for which most CROs medium and large are jockeying.

More... »

Pfizer's rheumatoid arthritis pill impresses experts despite study deaths

Wednesday, May 25, 2011 12:31 PM

Pfizer's new rheumatoid arthritis pill impressed experts at a medical meeting in London today, despite four deaths in a study that spooked investors last month, according to Reuters.

More... »

Pfizer files NDA for new oncology drug

Wednesday, May 18, 2011 12:07 PM

Pfizer has filed a new drug application for its oncology drug crizotinib with regulators in the U.S. and Japan.

More... »

Rigel assumes development responsibility for R343

Friday, May 6, 2011 12:37 PM

Rigel Pharmaceuticals will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several phase I clinical trials. Pfizer is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D.  Rigel is evaluating the details of R343's development to date and expects to design a phase II clinical trial with R343 later this year.

More... »

Aires Pharmaceuticals appoints Edwin L. Parsley as CMO

Wednesday, May 4, 2011 01:05 PM

Aires Pharmaceuticals has hired Ed Parsley, D.O., as chief medical officer.  Parsley will be responsible for all clinical development activities for Aironite, the company's lead product for treatment of pulmonary arterial hypertension (PAH).

More... »

Astellas adds four to team

Tuesday, May 3, 2011 12:33 PM

Astellas Pharma Global Development, a subsidiary of Tokyo-based Astellas Pharma, welcomes four new industry leaders to its team.

More... »

Analysts eye Pfizer break-up

Monday, May 2, 2011 01:22 PM

Analysts have been eyeing the prospect of a Pfizer break-up; they figure Pfizer would be worth $180 billion in pieces, according to Fierce Pharma.

More... »

Regulus Therapeutics appoints Neil W. Gibson as CSO

Monday, April 18, 2011 01:09 PM

Regulus Therapeutics, a biopharmaceutical company that discovers and develops new medicines targeting microRNAs, has appointed Neil Gibson, Ph.D., as its chief scientific officer. 

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »